Related Experiment Video
Updated: Dec 17, 2025
06:38
A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
14.0K
Neoadjuvant Therapy for Locally Advanced Renal Cell Carcinoma
Mary E Westerman1, Daniel D Shapiro1, Christopher G Wood1
1Department of Urology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1373, Houston, TX 77030, USA.
The Urologic Clinics of North America
|July 1, 2020
Summary
Neoadjuvant therapy shows promise for locally advanced renal cell carcinoma but currently lacks evidence for improved oncologic outcomes or tumor downstaging. Future research on immune checkpoint inhibitors may clarify its role.
Area of Science:
- Oncology
- Urology
Background:
- Locally advanced renal cell carcinoma (RCC) presents challenges in surgical resection and recurrence.
- Neoadjuvant therapy is explored to improve surgical outcomes and reduce recurrence rates in RCC.
Purpose of the Study:
- To evaluate the current evidence supporting neoadjuvant therapy in locally advanced renal cell carcinoma.
- To assess the efficacy of neoadjuvant treatments in achieving tumor downsizing and downstaging, particularly for inferior vena cava tumor thrombi.
Main Methods:
- Review of existing literature on neoadjuvant therapy for locally advanced renal cell carcinoma.
- Analysis of studies investigating targeted therapies and their impact on tumor size and stage.
Main Results:
- Current evidence does not support improved oncologic outcomes with neoadjuvant therapy in RCC.
- While targeted therapies can cause tumor downsizing, this rarely leads to downstaging.
- Neoadjuvant therapy is not currently recommended for downstaging inferior vena cava tumor thrombi.
Conclusions:
- Neoadjuvant therapy for locally advanced RCC has not demonstrated benefits in oncologic outcomes or downstaging.
- Further investigation into novel agents like immune checkpoint inhibitors is warranted to define a potential role for neoadjuvant therapy in RCC.
Related Concept Videos
01:26Kidney Transplant II: Surgical Procedure
206
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
206
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
193
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
193
01:16Kidney Transplant III: Nursing Management
240
Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...
240
01:27Tumor Immunotherapy
1.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.6K
01:11Renal Failure: Dose Adjustments
342
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
342